Markets | | | The screener enables traders to track the price movements of specific stocks and further monitor various signals and indicators. While the platform is not without its fair share of drawbacks, it is a useful resource for both new and experienced traders. Read the Full Story |
|
From Our Partners | | My top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to help regular investors generate enough income to become financially independent…
Without taking on excessive amounts of risk.
I’m talking about having the opportunity to collect $500 on Monday…
$563 on Wednesday…
Then as much as $625 on Friday. | | Click here to reserve a copy and put yourself on the path to better trading. |
|
Stocks | | | Active value managers and value as a portfolio factor have underperformed the indexes since the global financial crisis. This lead to mass redemptions from top value managers like Greenlight and Pershing Square, and the proclamation of value’s death from financial pundits.
Investment strategi... Read the Full Story |
|
Markets | | | Trulieve is a vertically integrated cannabis producer, this means that they cultivate cannabis and also sell it in their own retail stores. The company calls this “seed-to-sale” integration. They’re primarily a server of the Florida medical marijuana market, with a sizable portion ... Read the Full Story |
|
From Our Partners | | We’ve got seven great summertime plays for you. These stocks are in a prime position to reward your portfolio… especially if you take action before summer is in full swing!
They cover summer-centric industries such as solar, home improvement, entertainment, travel, and more.
To keep you motivated during these summer months, we’d like to give you a FREE report revealing these companies – 7 Best Stocks to Own in Summer 2025. | | Get Your Copy of "7 Best Stocks to Own in Summer 2025" Here. |
|
Markets | | | Quantitative investing is infinitely easier to implement on an individual level than it’s trading counterpart. It simply comes down to identifying factors that outperform and setting appropriate position balancing, risk management, and rebalancing criteria.
Investing quantitatively protects u... Read the Full Story |
|
Markets | | |
If you’re like most investors, you’ve spent a lot of time thinking about your retirement, and with good reason. According to the U.S. Census Bureau, the median household income is approximately $62,000. The average household income is only about $11,000 higher.
This means that the ave... Read the Full Story |
|
|
The Early Bird Stock Of The Day IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California. | | View Today's Stock Pick |
|
